scholarly journals Cost variation analysis study of oral anti-depressant drugs available in India

2017 ◽  
Vol 6 (4) ◽  
pp. 973
Author(s):  
Chaithra K. N. ◽  
Laxminarayana Kamath
Keyword(s):  
Economic Burden ◽  
Patient Adherence ◽  
Antidepressant Drug ◽  
Antidepressant Drugs ◽  
Adherence To Treatment ◽  
Price Variation ◽  
Medical Specialties ◽  
Cost Variation ◽  
Maximum Price ◽  
The Cost

Background: Depression is a disorder of major public health importance, in terms of its prevalence and the suffering, dysfunction, morbidity and economic burden. In India, the overall prevalence of depression is reported to be 15.9%. Antidepressant drugs are available in many different brands and costs of all brands are different. Patients of depression have to take the antidepressant drug for a long duration, so cost of the antidepressant drug influence the patient adherence to treatment and it is one of the important part of rational prescription.Methods: The cost of a particular drug being manufactured by different companies in the same strength and dosage forms was obtained from “Current Index of Medical Specialties” July-October, 2015, and “DrugsUpadate.com”. The cost ratio and percentage cost variation was calculated.Results: The prices of a total of 28 drugs (22 single and 6 combination preparations) available in 64 different formulations were analyzed. In single drug therapy, among Tri cyclic antidepressants (TCAs), Reboxetine (2 mg) showed the maximum price variation of 900%. In SSRIs, Dapoxetine (30 mg) showed the maximum price variation of 2360%. In SNRIs, Venlafaxine (75 mg) showed the maximum price variation of 109%. In Atypical antidepressants, Bupropion (150 mg) showed the maximum price variation of 515.38%. In RIMAs, Moclobemide (150 mg) showed the maximum price variation of 246.15% and in combination therapies, Amitriptyline with Chlordiazepoxide showed the maximum price variation of 129.35%.Conclusions: This study shows a wide variation in the prices of oral Anti-depressant drugs available in India. Psychiatrist/ Physician should consider the cost while prescribing antidepressant drugs. India being developing country most of the people belong to poor socioeconomic status, so prescribing same generic drug with low cost reduces economic burden and improves patient adherence to treatment which results in better outcome.

scholarly journals Cost variation analysis of parenteral antibiotics in Indian pharmaceutical market

2019 ◽  
Vol 8 (11) ◽  
pp. 2535
Author(s):  
Prasan R. Bhandari ◽  
Apeksha Bhandary
Keyword(s):  
Tertiary Care ◽  
Fixed Dose ◽  
Price Difference ◽  
Price Variation ◽  
Medical Specialties ◽  
Cost Variation ◽  
Maximum Price ◽  
Minimum Price ◽  
Dose Combination ◽  
The Cost

Background: The objective of the present study was to analyse price differences between parenteral antibiotics available in a tertiary care teaching hospital.Methods: The study was done in the Department of Pharmacology of S. D. M. College of Medical Sciences, Dharwad, Karnataka. Latest volume of current index of medical specialties or Indian Drug Review was used to analyze the prices of parenteral antibiotics.Results: Overall, prices of 17 single drug antibiotics available in 37 strengths marketed and 8 fixed-dose combinations available in 16 strength marketed were analyzed. It was observed that the maximum cost variation among the single ingredient parenteral antibiotic was with cefpirome 1000 mg. The price difference being Rs. 283 and the cost variation being 90.7%. The minimum price variation was seen with Ampicillin 100 mg of Rs. 4.3 and the cost variation being 40.2%. Additionally the highest price difference was also seen teicoplanin 400 mg i.e., Rs. 610 and its cost variation being 68.5%. Among the fixed-dose combination (FDC’s) the maximum price variation was observed in the combination of cefoperazone+sulbactum 1000+1000 of Rs. 340. Whereas the cost variation of the same was 212.5 %. The minimum price variation among the FDC’s was of the combination of ceftriaxone 250 mg + tazobactum 31.25 mg Rs. 3.3 and its cost variation being 7.9 %.Conclusions: Pharmacoeconomics facets must be taken into deliberation by healthcare practitioners while prescribing antibiotics to the patients for infectious disease treatment. This will assist compliance, reduce antibiotic resistance and treatment failure.

scholarly journals Cost variation analysis of ACE inhibitors in India

2017 ◽  
Vol 6 (6) ◽  
pp. 1522
Author(s):  
Prashant Wadagbalkar ◽  
Poonam Patel ◽  
Swati V. Raipurkar
Keyword(s):  
Ace Inhibitors ◽  
Antihypertensive Drugs ◽  
Patient Adherence ◽  
Antihypertensive Agents ◽  
Cost Ratio ◽  
Medical Specialties ◽  
Single Drug ◽  
Cost Variation ◽  
The Difference ◽  
The Cost

Background: Cardiovascular diseases are the most prevalent cause of death and disability in developed and developing countries. There is a wide variation in the prices of antihypertensive drugs marketed in India. Thus, a study was planned to find out variation in cost in the ACE Inhibitors available in India either as a single drug or in combination and to evaluate the difference in cost of various brands of the same ACE Inhibitors and ARBs by calculating percentage variation in cost in Indian rupees.Methods: Minimum and maximum costs in rupees (INR) of antihypertensive agents manufactured by different companies, in the same strength and dosage forms were obtained from “current index of medical specialties” January April 2016 and Drug Today October-December 2016. The cost ratio and percentage cost variation were calculated for each generic antihypertensive agent (ACE Inhibitors and ARBs).Results: This study shows that there is a wide variation in the prices of different brands of same ACE Inhibitors and ARBs in Indian market.Highest cost variation 400% is for Lisinopril (2.5mg), followed by Enalapril (10mg) 394.16%, Telmisartan (20mg) 322.22%.Conclusions: There is a wide difference in the cost of different brands of ACE Inhibitors and ARBs available in India. They have important role in management of hypertension particularly if associated with other morbidities like diabetes. The clinicians prescribing these drugs should be aware of these variations in cost so as to reduce the cost of drug therapy and increase the patient adherence to the therapy.

scholarly journals Disparity in cost of oral hypoglycemic agents available in Indian market

2019 ◽  
Vol 8 (12) ◽  
pp. 2631
Author(s):  
Dheeraj Kumar Singh ◽  
Mukesh Kumar ◽  
Soni .
Keyword(s):  
Communicable Disease ◽  
Health Sector ◽  
Hypoglycemic Agents ◽  
Oral Hypoglycemic Agents ◽  
Price Variation ◽  
Medical Specialties ◽  
Sodium Glucose Cotransporter ◽  
Maximum Price ◽  
The Right ◽  
The Cost

Background: Diabetes is one of the most common non-communicable disease worldwide, of which India has been crowned with the title of “diabetes capital of the world”. On an average a person spends 20% of his or her income for the treatment of diabetes per year. So, it’s become very important to conduct a complete cost disparity study among oral hypoglycemic agent available in the market. Information generated from the current analysis, will be helpful to doctors in choosing the right drug for their patient and for the health sector in successfully utilizing the available resources.Methods: The study was conducted in the department of pharmacology AIIMS, Patna 2019. Price of the drugs per tablet/capsule/vial were reviewed from “Current Index of Medical Specialties” January-April 2019 and “Drug Today” October-December, 2018 for analysis of different formulations of oral hypoglycemic agents.Results: The cost of total 16 drugs belonging to 6 different classes, available in 38 different formulations were analyzed. Total 44 different pharmaceutical companies were involved in the manufacture of oral hypoglycemic agents. Overall glibenclamide (5 mg) and bromocriptine (2.5 mg) showed maximum % price variation of 422.79 and 586.27 respectively. Dapagliflozin and canagliflozin both belonging to sodium glucose cotransporter-2 inhibitors shows minimum price variation of 9.86 and 0.9 respectively.Conclusions: The current study shows that there is a huge price variation among oral hypoglycemic agents manufactured by different companies and government needs to take essential steps to bring about the uniformity in the price.

scholarly journals Study of the Variation in Prices of Antidepressant Drugs Available in Nepali Market

2020 ◽  
Vol 5 (2) ◽  
pp. 1006-1010
Author(s):  
Anjan Khadka ◽  
Pradeep Manandhar ◽  
Nagendra Katuwal ◽  
Mahesh Khatri
Keyword(s):  
Tertiary Care Hospital ◽  
Tertiary Care ◽  
Antidepressant Drugs ◽  
Cost Ratio ◽  
Care Hospital ◽  
Cross Sectional ◽  
Medical Specialties ◽  
Cost Variation ◽  
Multiple Drugs ◽  
The Cost

Introduction: Depression often remains unrecognized, misdiagnosed and/or under treated. There are multiple drugs from multiple companies which are available for treatment of depression. The prices of same drug with different brands are variable which questions the afford ability of treatment to the patients and their compliance. Objective The study was conducted to analyze the cost variation of different brands of antidepressant drugs prescribed in a tertiary care hospital of Nepal. Methodology This study design was cross-sectional and method was quantitative method and conducted at department of pharmacology of a tertiary care hospital from September 2018 to January 2019 after getting approval from institutional review committee. The commonly prescribed antidepressant drugs were recorded from prescription records of department of psychiatry and their cost, cost ratio and percentage variation were calculated as per current index of medical specialties and National index of medical specialties. The data were recorded in MS excel and presented as simple descriptive statistics. Result The study included seven commonly prescribed antidepressants obtained from 214 prescription records. The cost of one course of citalopram 40 mg tablet was found to be higher and the cost of one course of imipramine 25 mg tablet was found to be lower. The maximum and minimum cost ratio was 2.46 and 1.08 with fluoxetine 20 mg capsule and dothiepin 50 mg tablet respectively. The maximum and minimum percentage of cost variation was with fluoxetine 20 mg capsule and dothiepin 50 mg tablet. Conclusion Costs of antidepressants had wider variations depending on the manufacturers and availability of different dose and brands.

scholarly journals Cost variation analysis of commonly prescribed anti-diabetic drugs available in Indian market: a pharmaco-economic study

2021 ◽  
Vol 11 (1) ◽  
pp. 47
Author(s):  
Kajal S. Gupta ◽  
Milind L. Pardeshi ◽  
Rajesh S. Hiray
Keyword(s):  
Minimum Cost ◽  
Rapid Expansion ◽  
Fixed Dose ◽  
Cost Ratio ◽  
Pharmaceutical Pricing ◽  
Price Variation ◽  
Medical Specialties ◽  
Cost Variation ◽  
The Government ◽  
The Cost

Background: Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary lifestyle, the incidence of DM is increasing. The chronic nature of DM causes significant personal suffering and economic difficulty to families. The was aimed at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various pharmaceutical companies were obtained from current index of medical specialties (CIMS) website, Indian drug review (IDR) 2021 issue and National pharmaceutical pricing authority-pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, metformin 500 mg sustained release showed highest price variation (3668%). Minimum cost variation was found with glipizide 2.5 mg (65%). Amongst the fixed dose combinations, highest cost variation was seen with glimepiride 2 mg+metformin 1000 mg (2703%) while minimum cost variation was found with repaglinide 1 mg+voglibose 0.3 mg (29%).Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all.Background:  Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary life style, the incidence of DM is increasing .The chronic nature of DM causes significant personal suffering and economic difficulty to families. The present study aims at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various brands were obtained from Current Index of Medical Specialties (CIMS) website, Indian Drug Review (IDR) 2021 issue and National Pharmaceutical Pricing Authority – Pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, Metformin 500mg Sustained Release showed highest price variation (3668%). Minimum cost variation was found with Glipizide 2.5mg (65%).Amongst the fixed dose combinations, highest cost variation was seen with Glimepiride 2mg + Metformin 1000mg (2703%) while minimum cost variation was found with Repaglinide 1mg + Voglibose 0.3mg (29%). Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all. Keywords: Anti-diabetic agents, Cost variation, Pharmaco-economics, Adherence, Brands   Background:  Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary life style, the incidence of DM is increasing .The chronic nature of DM causes significant personal suffering and economic difficulty to families. The present study aims at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various brands were obtained from Current Index of Medical Specialties (CIMS) website, Indian Drug Review (IDR) 2021 issue and National Pharmaceutical Pricing Authority – Pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, Metformin 500mg Sustained Release showed highest price variation (3668%). Minimum cost variation was found with Glipizide 2.5mg (65%).Amongst the fixed dose combinations, highest cost variation was seen with Glimepiride 2mg + Metformin 1000mg (2703%) while minimum cost variation was found with Repaglinide 1mg + Voglibose 0.3mg (29%). Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all. Keywords: Anti-diabetic agents, Cost variation, Pharmaco-economics, Adherence, Brands   Background:  Diabetes mellitus (DM) is a chronic metabolic disorder requiring lifelong treatment. Due to rapid expansion of urbanization, unhealthy diet habits and sedentary life style, the incidence of DM is increasing .The chronic nature of DM causes significant personal suffering and economic difficulty to families. The present study aims at investigating the cost difference in various brands of the same oral anti-diabetic drug.Methods: The minimum and the maximum cost in rupees (INR) of a particular anti-diabetic drug manufactured by various brands were obtained from Current Index of Medical Specialties (CIMS) website, Indian Drug Review (IDR) 2021 issue and National Pharmaceutical Pricing Authority – Pharma sahi daam. The cost ratio and percentage cost variation were noted for each brand.Results: Amongst single drug therapy, Metformin 500mg Sustained Release showed highest price variation (3668%). Minimum cost variation was found with Glipizide 2.5mg (65%).Amongst the fixed dose combinations, highest cost variation was seen with Glimepiride 2mg + Metformin 1000mg (2703%) while minimum cost variation was found with Repaglinide 1mg + Voglibose 0.3mg (29%). Conclusions: A noticeable cost variation was found in different brands of the same anti-diabetic drug. Prescribing a more expensive brand when a cheaper one is available can burden the patient financially and thus reduce patient compliance. In addition, the Government should also include more anti-diabetic drugs under the price control policy to ensure that affordable and efficacious medicines are available to all. Keywords: Anti-diabetic agents, Cost variation, Pharmaco-economics, Adherence, Brands         

scholarly journals Comparison of different brands of centrally acting skeletal muscle relaxants: a cost analysis study

2019 ◽  
Vol 8 (6) ◽  
pp. 1419
Author(s):  
Kiran B. ◽  
Kala P. ◽  
Chitra N. S. ◽  
Jamuna Rani R.
Keyword(s):  
Skeletal Muscle ◽  
Diclofenac Sodium ◽  
Cost Effective ◽  
Muscle Relaxants ◽  
Pharmaceutical Companies ◽  
Price Variation ◽  
Cost Variation ◽  
Maximum Price ◽  
Group A ◽  
The Cost

Background: Skeletal muscle relaxants are structurally distinct drugs prescribed for reducing muscle spasms, pain, and hyperreflexia. Centrally acting skeletal muscle relaxants are manufactured by various pharmaceutical companies with variable price. The present study, aimed to analyze the cost variation of various brands of centrally acting skeletal muscle relaxants, so as to help the physician to choose the cost effective treatment.Methods: Current index of medical stores (CIMS) April 2018 and online literature were used as information guide to review the prices of drugs used in the treatment of musculo skeletal pain and spastic neurological disorders.Results: Among anti spasmodic group, thiocolchicoside 4 mg shows maximum price variation of 337.5%, whereas carisoprodol 350 mg shows the least variation of 0.1%. It is evident from antispastic group that baclofen 10 mg shows maximum price variation of 93.91% and 5 mg of Baclofen shows the least variation of 11.22%. It is observed that, among anti spastic group, a percentage prize variation of 93.91 for 10 mg and 11.22 for 5 mg baclofen. Largest % prize variation is seen in metaxalone + diclofenac sodium (400+50) mg as 525% and the least variation is observed in tolperisone+ paracetamol (150+325) mg as 3.88%.Conclusions: Centrally acting orally effective skeletal muscle relaxants are commonly prescribed for painful musculoskeletal and spastic neurological disorders. Physicians should give due importance for the cost of the drugs while selecting appropriate drug for musculo skeletal disorders.

scholarly journals Cost comparisons of five leading brands of the antihypertensive drug, Telmisartan, available in an Indian city

2019 ◽  
Vol 8 (6) ◽  
pp. 1377
Author(s):  
Vikram A. Rajadnya ◽  
Sheena R. Bedi
Keyword(s):  
Antihypertensive Drug ◽  
Economic Burden ◽  
Annual Cost ◽  
Antihypertensive Drugs ◽  
Price Variation ◽  
Important Place ◽  
Cost Variation ◽  
Annual Budget ◽  
Indian City ◽  
The Cost

Background: Antihypertensive drugs have to be taken lifelong, after initiation of the treatment. Price variation can lead to huge economic burden on the patients of hypertension, especially when cost considerations are not undertaken by the prescribing physician . This study was undertaken to compare the annual cost , to the patient , of five different most commonly prescribed brands of Telmisartan 40 mg, in Kolhapur city.Methods: Authors purchased a strip of 10 tablets each of the five leading brands in one city, Kolhapur, India, of Telmisartan 40 milligram. The prices of the strip of 10 tablets of each of the five selected brands were compared.  In turn the annual cost of each of these five, was compared directly as well as using percentages. The data was collected, analysed and presented.Results: The data of the cost of the preparations of five different brands of a single antihypertensive drug, Temisartan 40 milligram shows that the annual cost of the costliest among the three brands of this drug is almost three times , that of the cheapest brand, or in other words almost 300 percent that of the cheapest brand.Conclusions: the cost variation amongst the five brands was considerable. India being a country with a major chunk of the population being very price sensitive, the prescribing physician must select the brand carefully. The most costly preparation of Temisartan can significantly add to the burden on the patient’s annual budget. Thus, Pharmacoeconomics must take an important place while prescribing medicines, especially in a country like India.

scholarly journals COST ANALYSIS OF DISEASE MODIFYING ANTI RHEUMATIC DRUGS: THE INDIAN SCENARIO

2020 ◽  
pp. 1-2
Author(s):  
Zarrin Ansari ◽  
Sharmada Nerlekar ◽  
Sagar Karia ◽  
Sudhir Pawar
Keyword(s):  
Rheumatoid Arthritis ◽  
Work Capacity ◽  
Biological Agents ◽  
Medical Specialties ◽  
Cost Variation ◽  
Conscious Choice ◽  
Socioeconomic Burden ◽  
Disease Modifying ◽  
The Cost ◽  
Indian Scenario

Background: Rheumatoid arthritis is a chronic, autoimmune and inflammatory disease affecting the joints and cartilages, eventually leading towards deformity and resultant disability. Today’s rheumatologists have an armamentarium of Disease Modifying Anti Rheumatic Drugs (DMARDs) to choose from. The chronicity of the disease, resultant deformities and reduced work capacity adds to the socioeconomic burden of the disease. This study aims to compare the costs of various brands of DMARDs (both biological and non-biological agents), so as the give the readers an idea about the cost range and variation present amongst the available DMARDs. Materials and Methods: Current Index of Medical Specialties (CIMS India) application was accessed in the month of August 2020 to note the cost of various brands of DMARDs. The information was tabulated. The cost difference and percentage cost variation was calculated and compared. Results:The maximum number of brands was available for methotrexate amongst the biological as well as non-biological agents. Least and highest percentage cost variation was observed for 2.5 mg strength of methotrexate and 100 mg of cyclosporine, respectively. In general, biologicals had fewer brands in the market as the cost was considerably higher than the non-biological agents. Conclusion:There is a wide variation amongst the costs of various DMARDs. This has its own advantages. Conscious choice of economical brands can profoundly effect the socioeconomic burden of rheumatoid arthritis management.

scholarly journals A study of the cost analysis of various oral antihypertensive drugs available in Indian market

2019 ◽  
Vol 8 (8) ◽  
pp. 1850
Author(s):  
Neelesh Arya ◽  
Shweta Agrawal ◽  
Mehul Agrawal
Keyword(s):  
Public Health ◽  
Effective Treatment ◽  
Antihypertensive Drugs ◽  
Public Health Problem ◽  
Price Variation ◽  
Medical Specialties ◽  
Average Percentage ◽  
Public Health Burden ◽  
Cost Effective Treatment ◽  
The Cost

Background: Hypertension is a serious global public health problem. It accounts for 10% of all deaths in India and is the leading non-communicable disease. Recent studies have shown that the prevalence of hypertension is 25% in urban and 10% in rural people in India. It exerts a substantial public health burden on cardiovascular health status and health care systems in India. Antihypertensive treatment effectively reduces hypertension related morbidity and mortality. The cost of medications has always been a barrier to effective treatment. The increasing prevalence of hypertension requires use of cost effective treatment for the effective management of the disease.Methods: Cost of a particular drug (cost per 10 tablets) in the same strength and dosage forms being manufactured by different companies was obtained from Current Index of Medical Specialties, Jan‑April 2019 and “Indian Drug Review” (IDR) September 2018. Difference between the maximum and minimum cost of the same drug manufactured by different pharmaceutical companies was calculated and percentage cost variation was calculated.Results: The prices of a total of 24 drugs (15 single and 9 combination preparations), available in 59 different formulations were analysed. These 62 formulations are manufactured by different pharmaceutical companies.Conclusions: The average percentage price variation of different brands of the same oral antihypertensive drug manufactured in India is very wide. The appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.

scholarly journals To study the cost variation analysis of oral H2 receptor blockers available in different brands in Indian pharmaceutical market

2019 ◽  
Vol 8 (4) ◽  
pp. 802
Author(s):  
Hansraj Kumar ◽  
Uma Shankar Prasad Keshri ◽  
Rajeev Kumar ◽  
Manju Gari ◽  
Akash Chandra
Keyword(s):  
Price Ratio ◽  
Price Variation ◽  
Ranitidine 150Mg ◽  
H2 Receptor ◽  
Cost Variation ◽  
Common Drug ◽  
Ranitidine 300Mg ◽  
H2 Receptor Blockers ◽  
Receptor Blockers ◽  
The Cost

Background: Aim of the study was to study percentage price variations among different brands of the commonly prescribed H2 receptor blockers.Methods: The maximum and minimum price of each brand of the drug in INR was noted by using CIMS January to April 2018 edition, Drug Today April to June 2018 Vol-1. The price ratio and the percentage price variation for individual drug brands was calculated. The price of 10 tablets/capsules were calculated. At last the price ratio and percentage price variation of various brands were compared.Results: Percentage variation in price for H2 receptor blockers marketed in India was found to be tablet cimetidine 200mg:81.89, tablet cimetidine 400mg:91.27, tablet ranitidine 150mg:295.64, tablet ranitidine 300mg:123.19, tablet famotidine 20mg:939.62, tablet famotidine 40mg:1110.09, tablet roxatidine 75mg:38.65, tablet roxatidine 150mg:21.85.Conclusions: H2 receptor blocker is the most common drug prescribed for prolonged period in case of gastritis, Gastro-Esophageal Reflux Disease (GERD), peptic ulcer. If a costly brand is prescribed, the patients have to pay more money unnecessarily for their treatment. The doctors prescribing these drugs should be aware of these variations in price to reduce the price of drug therapy.

Sign in / Sign up

Export Citation Format

Share Document